TY - JOUR

T1 - A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia

AU - Nørskov, Kristina Holmegaard

AU - Fridthjof, Katrine

AU - Kampmann, Peter

AU - Dünweber, Anne

AU - Andersen, Christen Lykkegaard

AU - Renaberg, Toni

AU - Schöllkopf, Claudia

AU - Ahmad, Syed Azhar

AU - Schou, Katrine

AU - Jensen, Cecilie Fremming

AU - Møller, Peter

AU - Lundholm, Birgitte Wolf

AU - Marcher, Claus

AU - Jepsen, Lene

AU - Ørntoft, Anne Katrine

AU - Ommen, Hans Beier

AU - Andersen, Lotte

AU - Behrentzs, Anni

AU - Hasselgren, Connie Fruergaard

AU - Severinsen, Marianne

AU - Grand, Mia Klinten

AU - Jarden, Mary

AU - Møller, Tom

AU - Kjeldsen, Lars

N1 - Publisher Copyright: © 2021 Elsevier Ltd

PY - 2022

Y1 - 2022

N2 - Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.

AB - Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.

KW - Acute myeloid leukemia

KW - Feasibility

KW - Home-based

KW - Intensive chemotherapy

KW - Outpatient

KW - Safety

U2 - 10.1016/j.leukres.2021.106756

DO - 10.1016/j.leukres.2021.106756

M3 - Journal article

C2 - 34839055

AN - SCOPUS:85119927292

VL - 112

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

M1 - 106756

ER -